Coenzyme M
- Generic Name
- Coenzyme M
- Brand Names
- Uromitexan
- Drug Type
- Small Molecule
- Chemical Formula
- C2H6O3S2
- CAS Number
- 3375-50-6
- Unique Ingredient Identifier
- VHD28S0H7F
- Background
Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Indication
Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Associated Conditions
- Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide
Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy
- Conditions
- Osteosarcoma
- Interventions
- Behavioral: QuestionnaireProcedure: Surgery
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT00673179
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia
- Conditions
- LeukemiaAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 220
- Registration Number
- NCT00671658
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2008-04-28
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 17
- Registration Number
- NCT00667927
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
MT2004-30: Tomotherapy for Solid Tumors
- Conditions
- SarcomaBrain and Central Nervous System TumorsKidney CancerLiver CancerRetinoblastoma
- Interventions
- Biological: filgrastimProcedure: stem cell transplantationRadiation: tomotherapyRadiation: total marrow irradiationRadiation: Whole lung radiation
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 23
- Registration Number
- NCT00623077
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma
- Conditions
- Neuroblastoma
- Interventions
- Drug: Hematopoietic FactorProcedure: Primary tumor resection
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 13
- Registration Number
- NCT00578864
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE
- Conditions
- Lymphoma, Non-HodgkinLeukemiaLymphoma, HodgkinCancerLymphoma
- Interventions
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 26
- Registration Number
- NCT00578461
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
T-Reg Cell Kinetics, Stem Cell Transplant, REGALE
- Conditions
- LeukemiaHodgkin LymphomaNon Hodgkin LymphomaMyeloproliferative Disorders
- Interventions
- Drug: ARA CRadiation: Total Body Irradiation (TBI)Biological: Campath-1hProcedure: Stem Cell Infusion
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 24
- Registration Number
- NCT00578539
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO
- Conditions
- Thalassemia
- Interventions
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 10
- Registration Number
- NCT00578292
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
Effects of Mesna on Homocysteine in Kidney Failure
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- Lawson Health Research Institute
- Target Recruit Count
- 10
- Registration Number
- NCT00524199
- Locations
- 🇨🇦
London Health Sciences Centre, London, Ontario, Canada
Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies
- Conditions
- LeukemiaLymphomaMyeloma
- Interventions
- Radiation: Radiation TreatmentProcedure: Stem Cell Transplantation (SCT)Procedure: Anti-third Party Cytolytic T-lymphocytes (CTL)
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2011-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT00473551
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.